Uveitis is an inflammatory disease of the uvea, constituting the 4th leading cause of legal blindness worldwide and the 3rd leading cause of avoidable blindness . It is not a rare condition, with an incidence of 17 to 52 per 100,000 population and a prevalence of 38 to 204 per 100,000 population. In the case of cortico-dependence, it is generally accepted to propose sparing with a conventional immunosuppressant, whose efficacy is estimated at around 70%, compared with biotherapies, which are considered more effective (over 90%) but only available as 2nd-line treatment. However, there are few studies on the failure factors of this first-line treatment, such as macular thickness , gender, or vitamin D deficiency. Risk factors for flare-ups are nevertheless known, notably ethnicity, and smoking. The aim of this study is to identify risk factors for treatment failure after three months of first-line immunosuppressive therapy in patients with chronic non-infectious uveitis at Amiens-Picardie University Hospital.

Inclusion Criteria:

• Age : > 18 years old
• Uveitis requiring immunosuppressive therapy.
• Including at least one posterior involvement according to the SUN terminology: posterior, or intermediate and posterior, or anterior and posterior, or panuveitis.

Exclusion Criteria:

• Uveitis associated with multiple sclerosis or systemic lupus erythematosus.
• Ocular involvement in Behcet's disease requiring biologic therapy as first-line immunosuppressive treatment.
• Uveitis without posterior segment involvement.
• Infectious uveitis.
• Patients objecting to the use of their personal data for research purposes.

Retrospective cohort study based on medical records of patients who received first-line immunosuppressive (IS) therapy for their uveitis. Patients with chronic non-infectious uveitis at Amiens-Picardie University Hospital, over the period from January 2013 to January 2023.